Table 3.
Predictive factors of cirrhosis development during the follow-up in patients without cirrhosis at baseline.
| Variables | Cirrhosis development |
Univariate analysis |
||||
|---|---|---|---|---|---|---|
| No (n = 356) | Yes (n = 26) | p value | Wald | HR (95% CI) | p value | |
| Age at entry (yr) | 55 (42-65) | 56 (44-62) | 0.768 | |||
| Female sex | 256 (72%) | 18 (69%) | 0.770 | |||
| AST (U/L) | 323 (85-957) | 563 (288-1,057) | 0.045 | |||
| ALT (U/L) | 455 (124-1,198) | 760 (323-1,170) | 0.138 | 0.022 | 1.000 (1.000–1.001) | 0.631 |
| Total bilirubin (mg/dl) | 1.7(0.80-7.80) | 6.4 (1-14.5) | 0.074 | |||
| ALP (x ULN) | 0.96 (0.61-1.44) | 1.26 (1.00-1.62) | 0.023 | 4.122 | 1.379 (1.011–1.879) | 0.018 |
| GGT (U/L) | 131 (49-226) | 132 (86-330) | 0.285 | |||
| IgG (g/L) | 17 (12-21) | 20 (14-35 | 0.026 | 5.834 | 1.03 (1.006–1.056) | 0.016 |
| INR | 1.10 (1.00-1.21) | 1.2 (1.03-1.58) | 0.088 | |||
| Platelets count (x109/L) | 227 (179-273) | 199 (147-27) | 0.079 | |||
| mHAI (n, %) | ||||||
| Grade | 8.00 (6.00-10.00) | 11 (8.00-12.00) | 0.001 | 6.681 | 1.181 (1.041–1.339) | 0.010 |
| Stage | 1 (0-2) | 1 (0-3) | 0.088 | |||
| Fibrosis (n, %) | 170 (48%) | 17 (65% | 0.050 | 2.779 | 2.115 (0.877–5.102) | 0.096 |
| Advanced fibrosis (n, %) | 42 (12%) | 7 (27%) | 0.017 | 5.799 | 3.052 (1.231–7.568) | 0.016 |
| ANA (n, %) | 241 (68%) | 24 (92%) | 0.010 | |||
| SMA (n, %) | 269 (76%) | 22 (85%) | 0.338 | |||
| Anti-SLA/LP (n, %) | 23 (6.5%) | 1 (3.8%) | 0.588 | |||
| Anti-LKM1 (n, %) | 10 (2.0%) | 0 (0%) | 0.378 | |||
| Cs + AZA (n, %) | 197 (55%) | 18 (69 %) | 0.168 | |||
| Cs + MMF (n, %) | 102 (29%) | 4 (15.4%) | 0.145 | |||
| BLSM (kPa) | 5.4 (4.3-7.08) | 11.05 (8.58-15.93) | <0.001 | 50.148 | 1.204 (1.144–1.267) | <0.001 |
| BR at BLSM (n, %) | 288 (81%) | 10 (39%) | <0.001 | 19. 108 | 0.172 (0.078–0.378) | <0.001 |
| Time from diagnosis to BLSM (yr) | 2.19 (1.21-4.98) | 1.75 (1.13-3.62) | 0.524 | |||
ALP, alkaline phosphatase; ALT, alanine aminotransferase; ANA, antinuclear antibodies; Anti-LKM1, anti-liver kidney microsomal antibodies; anti-SLA/LP, anti-soluble liver antigen/liver pancreas antibodies; AST, aspartate aminotransferase; AZA, azathioprine; BLSM, first liver stiffness measurement after 6 months of treatment initiation; BR, biochemical response; Cs, corticosteroids; GGT, gamma-glutamyltransferase; HR, hazard ratio; INR, international normalised ratio; mHAI, modified hepatitis activity index; MMF, mycophenolate mofetil; SMA, smooth muscle antibodies.
Data are expressed as the median (IQR). Univariate analysis was performed by Cox regression.